RHJA
AGRX

Rice Hall James & Associates’s Agile Therapeutics AGRX Stock Holding History

Rice Hall James & Associates’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15
Closed -$176K – 315
2016
Q4 		$176K Buy
15
+2
+15% +$28K 0.01% 292
2016
Q3 		$179K Hold
13
– – 0.01% 293
2016
Q2 		$193K Hold
13
– – 0.01% 292
2016
Q1 		$158K Hold
13
– – 0.01% 292
2015
Q4 		$253K Buy
+13
New +$206K 0.01% 288

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Rice Hall James & Associates's AGRX Position: Q1 2017 in Review

Rice Hall James & Associates sold out of Agile Therapeutics (AGRX) in Q1 2017, closing a stake of 15 shares — an estimated $176K sold.

Rice Hall James & Associates first reported a position in AGRX in Q4 2015 and held it in 5 quarters. The position peaked at $253K in Q4 2015. 48 funds tracked by Wall St. Rank hold AGRX as of Q1 2017.

  • Rice Hall James & Associates reported no remaining Agile Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Rice Hall James & Associates sold 15 Agile Therapeutics shares in Q1 2017, an estimated $176K.
  • Rice Hall James & Associates first reported a position in Agile Therapeutics in Q4 2015 and held it in 5 quarters.
  • Rice Hall James & Associates's Agile Therapeutics position peaked at $253K in Q4 2015.
  • 48 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2017.

Based on Rice Hall James & Associates's 13F filing for Q1 2017, filed 19 Apr 2017.